Attached files
| file | filename |
|---|---|
| EX-10.1 - RESPONSE GENETICS INC | v183489_ex10-1.htm |
| 8-K - RESPONSE GENETICS INC | v183489_8k.htm |
FOR
IMMEDIATE RELEASE
| Investor Relations Contact: | Media Relations Contact: |
| Peter Rahmer | Barry Sudbeck |
| Trout Group | Fleishman-Hillard |
| 646-378-2973 | 415-318-4261 |
Response
Genetics, Inc. Appoints Chief Financial Officer
LOS ANGELES, May 05, 2010 —
Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and
commercialization of molecular diagnostic tests for cancer, announced today the
addition of David D. O’Toole as the Company’s vice president and chief financial
officer. In his role as CFO, Mr. O’Toole will be responsible for all aspects of
financial management for Response Genetics.
“I look
forward to working with David and am pleased he has joined our Executive
Management Team,” said Kathleen Danenberg, president and CEO of Response
Genetics. “David brings extensive finance and management expertise to the
Company and we expect that his range of experience in life science companies
will help contribute to the long-term success of the Company.”
Mr.
O’Toole brings to Response Genetics over 26 years of accounting, business and
finance experience primarily focused on global companies and the life science
and biotechnology industry. Mr. O’Toole was most recently CFO at Abraxis
Biosciences, Inc., a publicly traded biotechnology company with a $2 billion
market capitalization. Prior to Abraxis, Mr. O’Toole was a partner at Deloitte
& Touche LLP, where he was responsible for managing services for many large
and medium sized life science and biotechnology companies. Mr. O’Toole holds a
Bachelor of Science degree in accounting from the University of
Arizona.
Commenting
on his appointment, Mr. O’Toole said, “I am thrilled to have the opportunity to
join Response Genetics. I look forward to working with other members
of the management team and the Board as we focus on realizing the full potential
of the Company and create greater value for our shareholders.”
About
Response Genetics, Inc.
Response
Genetics, Inc. (“RGI”) (the “Company”) (Nasdaq: RGDX) is engaged in the research
and development of pharmacogenomic cancer diagnostic tests based on its
proprietary and patented technologies. RGI’s technologies enable extraction and
analysis of genetic information from genes derived from tumor samples stored as
formalin-fixed and paraffin-embedded specimens. In addition to diagnostic
testing services, RGI generates revenue from the sales of its proprietary
analytical pharmacogenomic testing services of clinical trial specimens to the
pharmaceutical industry. The Company was founded in 1999 and its principal
headquarters are located in Los Angeles, California. For more information,
please visit www.responsegenetics.com.
Page 1 of
3
-
more -
Page 2 of
3
Forward-Looking
Statement Notice
Except
for the historical information contained herein, this press release and the
statements of representatives of RGI related thereto contain or may contain,
among other things, certain forward-looking statements, within the meaning of
the Private Securities Litigation Reform Act of 1995.
Such
forward-looking statements involve significant risks and uncertainties. Such
statements may include, without limitation, statements with respect to the
Company’s plans, objectives, projections, expectations and intentions, such as
the ability of the Company to analyze cancer samples, the potential for using
the results of this research to develop diagnostic tests for cancer, the
responsibilities of the chief financial officer, and other statements identified
by words such as “projects,” “may,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans” or similar
expressions.
These
statements are based upon the current beliefs and expectations of the Company’s
management and are subject to significant risks and uncertainties, including
those detailed in the Company’s filings with the Securities and Exchange
Commission. Actual results, including, without limitation, actual sales results,
if any, or the application of funds, may differ from those set forth in the
forward-looking statements. These forward-looking statements involve certain
risks and uncertainties that are subject to change based on various factors
(many of which are beyond the Company’s control). The Company undertakes no
obligation to publicly update forward-looking statements, whether because of new
information, future events or otherwise, except as required by law.
###
Page 3 of
3